IRINOTECAN HYDROCHLORIDE

IRINOTECAN HYDROCHLORIDE
(eye-ri-no'te-can)
Camptosar
Classifications: antineoplastic; camptothecin;
Therapeutic: antineoplastic

Prototype: Topotecan
Pregnancy Category: D

Availability

20 mg/mL injection

Action

Irinotecan is a camptothecin analog that displays antitumor activity by inhibiting the intranuclear enzyme topoisomerase I. Thus, it is a strong inhibitor of DNA and RNA synthesis. Topoisomerase I is an essential intranuclear enzyme that relaxes the supercoiled DNA, thus enabling replication and transcription to take place. By inhibiting topoisomerase I, irinotecan and its active metabolite SN-38 cause double-stranded DNA damage during the synthesis (S) phase of DNA synthesis.

Therapeutic Effect

Irinotecan inhibits both DNA and RNA synthesis.

Uses

Metastatic carcinoma of colon or rectum.

Contraindications

Previous hypersensitivity to irinotecan, topotecan, or other camptothecin analogs; acute infection, diarrhea, pregnancy (category D), lactation. Safety and effectiveness in children are not established.

Cautious Use

Gastrointestinal disorders, myelosuppression, renal or hepatic function impairment, history of bleeding disorders, previous cytotoxic or radiation therapy.

Route & Dosage

Metastatic Carcinoma
Adult: IV 125 mg/m2 once weekly for 4 wk, then a 2-wk rest  period (future courses may be adjusted to range from 50 to 150 mg/m2 depending on tolerance; see complete prescribing information for specific dosage adjustment recommendations based on toxic effects)

Administration

Intravenous
  • Administer only after premedication (at least 30 min prior) with an antiemetic.
  • Wash immediately with soap and water if skin contacts drug during preparation.

PREPARE: IV Infusion: Dilute the ordered dose in enough D5W (preferred) or NS to yield a concentration of 0.12–2.8 mg/mL. Typical amount of diluent used is 250–500 mL.  

ADMINISTER: IV Infusion: Infuse over 90 min. Closely monitor IV site; if extravasation occurs, immediately flush with sterile water and apply ice.  

INCOMPATIBILITIES Y-site: Gemcitabine.

  • Store undiluted at 15°–30° C (59°–86° F) and protect from light. Use reconstituted solutions within 24 h.

Adverse Effects (≥1%)

Body as a Whole: Asthenia, fever, pain, chills, edema, abdominal enlargement, back pain. CNS: Headache, insomnia, dizziness. CV: Vasodilation/flushing. GI: Diarrhea (early and late onset), dehydration, nausea, vomiting, anorexia, weight loss, constipation, abdominal cramping and pain, flatulence, stomatitis, dyspepsia, increased alkaline phosphatase and AST. Hematologic: Leukopenia, neutropenia, anemia. Respiratory: Dyspnea, cough, rhinitis. Skin: Alopecia, sweating, rash.

Interactions

Drug: anticoagulants, antiplatelet agents, nsaids may increase risk of bleeding; carbamazepine, phenytoin, phenobarbital may decrease irinotecan levels. Herbal: St. John's wort may decrease irinotecan levels.

Pharmacokinetics

Peak: 1 h. Distribution: Irinotecan is 30% protein bound; active metabolite SN-38 is 95% protein bound. Metabolism: In liver by carboxylesterase enzyme to active metabolite SN-38. Elimination: 10 h for SN-38; 20% excreted in urine. Half-Life: 10–20 h.

Nursing Implications

Assessment & Drug Effects

  • Lab tests: Monitor WBC with differential, Hgb, and platelet count before each dose; monitor closely coagulation parameters especially with concurrent use of other drugs which affect these parameters.
  • Lab tests: Monitor fluid and electrolyte balance closely during and after periods of diarrhea. Monitor liver and renal function tests and blood glucose periodically.
  • Monitor for acute GI distress, especially early diarrhea (within 24 h of infusion), which may be preceded by diaphoresis and cramping, and late diarrhea (>24 h after infusion).

Patient & Family Education

  • Learn about common adverse effects and measures to control or minimize when possible.
  • Notify physician immediately when you experience diarrhea, vomiting, and S&S of infection. Diarrhea requires prompt treatment to prevent serious fluid and electrolyte imbalances.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(26)
© 2006-2017 medpill.info Last Updated On: 10/14/2017 (0)
Top site ratings
×
Wait 20 seconds...!!!